431 related articles for article (PubMed ID: 28802755)
1. Pneumococcal conjugate vaccination response in patients after community-acquired pneumonia, differences in patients with S. pneumoniae versus other pathogens.
Wagenvoort GHJ; Vlaminckx BJM; van Kessel DA; Geever RCL; de Jong BAW; Grutters JC; Bos WJW; Meek B; Rijkers GT
Vaccine; 2017 Sep; 35(37):4886-4895. PubMed ID: 28802755
[TBL] [Abstract][Full Text] [Related]
2. Impact of pneumococcal vaccination in children on serotype distribution in adult community-acquired pneumonia using the serotype-specific multiplex urinary antigen detection assay.
Pletz MW; Ewig S; Rohde G; Schuette H; Rupp J; Welte T; Suttorp N; Forstner C;
Vaccine; 2016 Apr; 34(20):2342-8. PubMed ID: 27016653
[TBL] [Abstract][Full Text] [Related]
3. A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the Netherlands.
Gessner BD; Jiang Q; Van Werkhoven CH; Sings HL; Webber C; Scott D; Gruber WC; Grobbee DE; Bonten MJM; Jodar L
Vaccine; 2019 Jul; 37(30):4147-4154. PubMed ID: 31155413
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: A case-control test-negative design study.
Lawrence H; Pick H; Baskaran V; Daniel P; Rodrigo C; Ashton D; Edwards-Pritchard RC; Sheppard C; Eletu SD; Litt D; Fry NK; Rose S; Trotter C; McKeever TM; Lim WS
PLoS Med; 2020 Oct; 17(10):e1003326. PubMed ID: 33095759
[TBL] [Abstract][Full Text] [Related]
5. Streptococcus pneumoniae serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN).
LeBlanc JJ; ElSherif M; Ye L; MacKinnon-Cameron D; Ambrose A; Hatchette TF; Lang ALS; Gillis HD; Martin I; Demczuk W; Andrew MK; Boivin G; Bowie W; Green K; Johnstone J; Loeb M; McCarthy AE; McGeer A; Semret M; Trottier S; Valiquette L; Webster D; McNeil SA
Vaccine; 2019 Aug; 37(36):5466-5473. PubMed ID: 31345638
[TBL] [Abstract][Full Text] [Related]
6. Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged ≥50 years with community-acquired pneumonia.
Sherwin RL; Gray S; Alexander R; McGovern PC; Graepel J; Pride MW; Purdy J; Paradiso P; File TM
J Infect Dis; 2013 Dec; 208(11):1813-20. PubMed ID: 24092845
[TBL] [Abstract][Full Text] [Related]
7. Direct and indirect effects of the 13-valent pneumococcal conjugate vaccine administered to infants and young children.
Esposito S; Principi N;
Future Microbiol; 2015; 10(10):1599-607. PubMed ID: 26439470
[TBL] [Abstract][Full Text] [Related]
8. Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia.
Rodrigo C; Bewick T; Sheppard C; Greenwood S; Mckeever TM; Trotter CL; Slack M; George R; Lim WS
Eur Respir J; 2015 Jun; 45(6):1632-41. PubMed ID: 25792633
[TBL] [Abstract][Full Text] [Related]
9. Pneumococcal conjugate vaccine use in adults - Addressing an unmet medical need for non-bacteremic pneumococcal pneumonia.
Sings HL
Vaccine; 2017 Sep; 35(40):5406-5417. PubMed ID: 28602602
[TBL] [Abstract][Full Text] [Related]
10. 13-Valent vaccine serotype pneumococcal community acquired pneumonia in adults in high clinical risk groups.
Daniel P; Rodrigo C; Bewick T; Sheppard C; Greenwood S; McKeever TM; Trotter C; Lim WS
Vaccine; 2018 Mar; 36(12):1614-1620. PubMed ID: 29439865
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design.
McLaughlin JM; Jiang Q; Isturiz RE; Sings HL; Swerdlow DL; Gessner BD; Carrico RM; Peyrani P; Wiemken TL; Mattingly WA; Ramirez JA; Jodar L
Clin Infect Dis; 2018 Oct; 67(10):1498-1506. PubMed ID: 29790925
[TBL] [Abstract][Full Text] [Related]
12. The burden of PCV13 serotypes in hospitalized pneumococcal pneumonia in Spain using a novel urinary antigen detection test. CAPA study.
Menéndez R; España PP; Pérez-Trallero E; Uranga A; Méndez R; Cilloniz C; Marimón JM; Cifuentes I; Méndez C; Torres A
Vaccine; 2017 Sep; 35(39):5264-5270. PubMed ID: 28823622
[TBL] [Abstract][Full Text] [Related]
13. Pneumococcal conjugate serotype distribution and predominating role of serotype 3 in German adults with community-acquired pneumonia.
Forstner C; Kolditz M; Kesselmeier M; Ewig S; Rohde G; Barten-Neiner G; Rupp J; Witzenrath M; Welte T; Pletz MW;
Vaccine; 2020 Jan; 38(5):1129-1136. PubMed ID: 31761500
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
[TBL] [Abstract][Full Text] [Related]
16. The potential role of 13-valent pneumococcal conjugate vaccine in preventing respiratory complications in bacteraemic pneumococcal community-acquired pneumonia.
Sanz-Herrero F; Gimeno-Cardona C; Tormo-Palop N; Fernández-Fabrellas E; Briones ML; Cervera-Juan Á; Blanquer-Olivas J
Vaccine; 2016 Apr; 34(15):1847-52. PubMed ID: 26845737
[TBL] [Abstract][Full Text] [Related]
17. Impact of the pediatric 13-valent pneumococcal conjugate vaccine on serotype distribution and clinical characteristics of pneumococcal pneumonia in adults: The Japan Pneumococcal Vaccine Effectiveness Study (J-PAVE).
Sando E; Suzuki M; Furumoto A; Asoh N; Yaegashi M; Aoshima M; Ishida M; Hamaguchi S; Otsuka Y; Morimoto K
Vaccine; 2019 May; 37(20):2687-2693. PubMed ID: 30975569
[TBL] [Abstract][Full Text] [Related]
18. The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on serotype 19A invasive pneumococcal disease.
Principi N; Esposito S
Expert Rev Vaccines; 2015; 14(10):1359-66. PubMed ID: 26289973
[TBL] [Abstract][Full Text] [Related]
19. PCV13-vaccinated children still carrying PCV13 additional serotypes show similar carriage density to a control group of PCV7-vaccinated children.
Dagan R; Juergens C; Trammel J; Patterson S; Greenberg D; Givon-Lavi N; Porat N; Gruber WC; Scott DA
Vaccine; 2017 Feb; 35(6):945-950. PubMed ID: 28087146
[TBL] [Abstract][Full Text] [Related]
20. Pediatric Complicated Pneumonia Caused by Streptococcus pneumoniae Serotype 3 in 13-Valent Pneumococcal Conjugate Vaccinees, Portugal, 2010-2015.
Silva-Costa C; Brito MJ; Pinho MD; Friães A; Aguiar SI; Ramirez M; Melo-Cristino J; ;
Emerg Infect Dis; 2018 Jul; 24(7):1307-1314. PubMed ID: 29912700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
